Literature DB >> 26581584

Patients with normocalcemic primary hyperparathyroidism may have similar metabolic profile as hypercalcemic patients.

Feyza Yener Ozturk1, Selvinaz Erol, Muhammed Masum Canat, Savas Karatas, Idris Kuzu, Sezin Dogan Cakir, Yuksel Altuntas.   

Abstract

Primary hyperparathyroidism is well known to be associated with cardiovascular morbidity and mortality. However, it is unclear whether normocalcemic primary hyperparathyroidism (NC-PHPT) and hypercalcemic primary hyperparathyroidism (HC-PHPT) share the same risk factors. We aimed to determine prevalence of metabolic syndrome in NC-PHPT and compare metabolic syndrome parameters and insulin resistance in NC-PHPT subjects with those in HC-PHPT and control subjects. After excluding patients with secondary hyperparathyroidism, the study enrolled 25 patients with NC-PHPT, 24 patients with HC-PHPT and 30 age-gender matched controls. All participants were evaluated using the International Diabetes Federation (IDF)-2006 metabolic syndrome criteria. Compared with HC-PHPT patients, NC-PHPT patients had similar prevalence of metabolic syndrome, glucose intolerance, and previous history of hypertension/anti-hypertensive medications, but compared with controls, NC-PHPT patients had significantly higher prevalence of glucose intolerance and previous history of hypertension/anti-hypertensive medications. Not serum calcium but PTH concentration was found to be significantly higher in those with glucose intolerance. Serum fasting triglyceride concentration and waist circumference were found to be positively correlated only with serum PTH concentration. In conclusion, patients with NC-PHPT may be prone to similar metabolic disturbances linked to higher cardiovascular risk like patients with HC-PHPT. Although NC-PHPT is thought to occur early in the development of the classical disease, it should be monitored regularly because of its metabolic consequences.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26581584     DOI: 10.1507/endocrj.EJ15-0392

Source DB:  PubMed          Journal:  Endocr J        ISSN: 0918-8959            Impact factor:   2.349


  7 in total

1.  US-guided microwave ablation for primary hyperparathyroidism: a safety and efficacy study.

Authors:  Bo-Qiang Fan; Xiao-Wei He; Huan-Huan Chen; Wei-Ming Zhang; Wei Tang
Journal:  Eur Radiol       Date:  2019-03-19       Impact factor: 5.315

Review 2.  Normocalcaemic primary hyperparathyroidism: a diagnostic and therapeutic algorithm.

Authors:  Joaquín Gómez-Ramírez; Radu Mihai
Journal:  Langenbecks Arch Surg       Date:  2017-08-19       Impact factor: 3.445

Review 3.  Primary hyperparathyroidism and hypertension.

Authors:  Sarah B Fisher; Nancy D Perrier
Journal:  Gland Surg       Date:  2020-02

4.  Parathyroidectomy improves cardiovascular risk factors in normocalcemic and hypercalcemic primary hyperparathyroidism.

Authors:  Selvihan Beysel; Mustafa Caliskan; Muhammed Kizilgul; Mahmut Apaydin; Seyfullah Kan; Mustafa Ozbek; Erman Cakal
Journal:  BMC Cardiovasc Disord       Date:  2019-05-08       Impact factor: 2.298

5.  Occult Renal Calcifications in Patients with Normocalcemic Primary Hyperparathyroidism and Their Association with the Parathyroid Hormone-Vitamin D Axis.

Authors:  Fernanda Victor; Alyne Layane Pereira Lemos; Anna Mirella de Holanda Ribas; Leonardo Bandeira; José Henrique Pimentel; Luiz Otávio de Andrade Damázio; Francisco Bandeira
Journal:  Int J Endocrinol       Date:  2022-04-08       Impact factor: 2.803

6.  Improving Glucose Homeostasis after Parathyroidectomy for Normocalcemic Primary Hyperparathyroidism with Co-Existing Prediabetes.

Authors:  Spyridon Karras; Cedric Annweiler; Dimitris Kiortsis; Ioannis Koutelidakis; Kalliopi Kotsa
Journal:  Nutrients       Date:  2020-11-16       Impact factor: 5.717

Review 7.  Immunomodulatory Potential of Diuretics.

Authors:  Paweł Bryniarski; Katarzyna Nazimek; Janusz Marcinkiewicz
Journal:  Biology (Basel)       Date:  2021-12-11
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.